Company: INMB
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001213900-25-021719
Chunk: 44

Company: Inmune Bio, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 44
---
 securities directly to institutional
investors or others who may be deemed to be underwriters within the meaning of the Securities Act of 1933 with respect to any sale of
those securities. The terms of any such sales will be described in the prospectus supplement.

Delayed Delivery Contracts

If the prospectus supplement indicates, we may
authorize agents, underwriters or dealers to solicit offers from certain types of institutions to purchase securities at the public offering
price under delayed delivery contracts. These contracts would provide for payment and delivery on a specified date in the future. The
contracts would be subject only to those conditions described in the prospectus supplement. The applicable prospectus supplement will
describe the commission payable for solicitation of those contracts.

Continuous Offering Program

Without limiting the generality of the foregoing,
we may enter into a continuous offering program equity distribution agreement with a broker-dealer, under which we may offer and sell
shares of our common stock from time to time through a broker-dealer as our sales agent. If we enter into such a program, sales of the
shares of common stock, if any, will be made by means of ordinary brokers’ transactions on Nasdaq at market prices, block transactions
and such other transactions as agreed upon by us and the broker-dealer. Under the terms of such a program, we also may sell shares of
common stock to the broker-dealer, as principal for its own account at a price agreed upon at the time of sale. If we sell shares of common
stock to such broker-dealer as principal, we will enter into a separate terms agreement with such broker-dealer, and we will describe
this agreement in a separate prospectus supplement or pricing supplement.

<div align='center'>11</div>

Market Making, Stabilization and Other Transactions

Unless the applicable prospectus supplement states
otherwise, other than our common stock all securities we offer under this prospectus will be a new issue and will have no established
trading market. We may elect to list offered securities on an exchange or in the over-the-counter market. Any underwriters that we use
in the sale of offered securities may make a market in such securities, but may discontinue such market making at any time without notice.
Therefore, we cannot assure you that the securities will have a liquid trading market.

Any underwriter may also engage in stabilizing
transactions, syndicate covering transactions and penalty bids in accordance with Rule 104 under the Securities Exchange Act of 1934
(the “Exchange Act”). St